December 7, 2016 / 12:05 PM / in 7 months

BRIEF-Aerie Pharma completes enrollment of mercury 2 phase 3 registration trial of roclatan

1 Min Read

Dec 7 (Reuters) - Aerie Pharmaceuticals Inc:

* Aerie pharmaceuticals completes enrollment of mercury 2 phase 3 registration trial of roclatan(tm) (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%

* Aerie pharmaceuticals-mercury 2,which commenced in march 2016, is 90-day registration trial with a topline efficacy readout expected in q2 of 2017

* Aerie pharmaceuticals inc - trial on track for topline 90-day efficacy readout in q2 2017

* Aerie pharmaceuticals inc - continue to expect to file an nda for roclatan(tm) ophthalmic solution near year-end 2017

* Aerie pharmaceuticals inc - plans to commence in first half of 2017 a third phase 3 registration trial for roclatan(tm), named mercury 3 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below